Immune-Onc scores $73m

Palo Alto, California-based Immune-Onc, a cancer immunotherapy company, has secured $73 million in Series B1 and B2 financing.

Palo Alto, California-based Immune-Onc, a cancer immunotherapy company, has secured $73 million in Series B1 and B2 financing. Oceanpine Capital led the round with participation from other investors that included Octagon Capital, Sphera Healthcare, Northern Light Venture Capital and Vivo Capital.

Source: Press Release